The use of Virtual Reality in psychotherapy for depressio

Phase 4

• Conditions: F32; F33; F34; Depressive episode; Recurrent depressive disorder; Persistent mood [affective] disorders

• Registration Number: DRKS00024981
• Lead Sponsor: niversitätsklinikum Düsseldorf, Klinisches Institut für Psychosomatische Medizin und Psychotherapie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-04-07
• Study Completion: 2021-11-19
• Results First Posted: 2024-01-26
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Depression symptomatology (ICD-10: F32 - 34)
- Inpatient treatment at the clinic for Psychosomatics and Psychotherapy, LVR-Klinikum Düsseldorf

Exclusion Criteria

- COVID-19 disease in an infectious phase or symptoms suggestive of COVID-19 disease.
- Last alcohol consumption less than 8 hours ago
- insufficient knowledge of the German language
- uncorrected visual loss and visual disturbances
- insufficiently corrected hearing
- Neurological/psychiatric pre-existing diseases affecting the vestibular organ, impairing the sense of balance or altering visual perception (e.g. Meniere's disease, dementia, post-stroke condition, psychosis)
- known epilepsy
- taking medications that affect eye movements
(lithium, carbamazepine, lamotrigine, topiramate, phenytoin, risperidone, haloperidol, phenobarbital or primidone)
- a body mass index (BMI) less than or equal to 17

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
BDI-II (Beck-Depression Inventar), Paper-Pencil questionaire, Depression severity, pre measurement (study inclusion) & post-measurement (end of inpatient treatment in clinic).<br><br>Four statements are given for each of 21 symptoms of depression (based on the DSM-IV criteria for major depression), from which the one that best describes how the assessor has felt in the past two weeks is to be selected. Completion time: between 5 and 10 minutes. Numerous studies have used the BDI-II (Cronbach's Alpha Depressed Patients in Treatment (N = 288) = .93). In different samples, there were high levels of agreement with both self-rated depressiveness (FDD-DSM-IV), r = .72 to .89, and with other-rated depressiveness (MADRS), r = .68 to .70.

Secondary Outcome Measures

Name	Time	Method
PSSUQ (Post Study System Usability Questionaire), global Usability of the VR-Intervention, post-measurement (end of inpatient treatment in clinic)